Journal Article Practice Guideline Systematic Review Meta-Analysis Ppublish 5 citations
PubMed: 38339996 DOI: 10.1093/jpids/piad116
Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce.
J Pediatric Infect Dis Soc 13(3):159-185
Authors: Zachary I Willis, Carlos R Oliveira, Mark J Abzug, Brenda I Anosike, Monica I Ardura, Laura L Bio, Juri Boguniewicz, Kathleen Chiotos, Kevin Downes, Steven P Grapentine, Adam L Hersh, Sarah M Heston, Diego R Hijano, W Charles Huskins, Scott H James, Sarah Jones, Christine R Lockowitz, Elizabeth C Lloyd, Christine MacBrayne, Gabriela M Maron, Molly Hayes McDonough, Christine M Miller, Theodore H Morton, Rosemary M Olivero, Rachel C Orscheln, Hayden T Schwenk, Prachi Singh, Vijaya L Soma, Paul K Sue, Surabhi B Vora, Mari M Nakamura, Joshua Wolf
Affiliations
- Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
- Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA.
- Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, USA.
- Department of Pediatrics, The Children's Hospital at Montefiore and Albert Einstein College of Medicine, Bronx, NY, USA.
- Department of Pediatrics, ID Host Defense Program, Nationwide Children's Hospital & The Ohio State University, Columbus, OH, USA.
- Department of Pharmacy, Lucile Packard Children's Hospital, Stanford, CA, USA.
- Departments of Anesthesiology, Critical Care Medicine, and Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Divisions of Critical Care Medicine and Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
- Department of Pediatrics, Perelman School of Medicine of the University of Pennsylvania, Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
- Department of Pharmacy, University of California San Francisco Benioff Children's Hospital, San Francisco, CA, USA.
- Department of Pediatrics, Division of Infectious Diseases, University of Utah, Salt Lake City, UT, USA.
- Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
- Department of Infectious Diseases, St. Jude Children's Research Hospital and Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, USA.
- Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.
- Department of Pediatrics, Division of Pediatric Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA.
- Department of Pharmacy, Boston Children's Hospital, Boston, MA, USA.
- Department of Pharmacy, St. Louis Children's Hospital, St. Louis, Missouri, USA.
- Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA.
- Department of Pharmacy, Children's Hospital Colorado, Aurora, CO, USA.
- Center for Healthcare Quality & Analytics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
- Department of Pharmacy, St Jude's Children's Research Hospital, Memphis, Tennessee, USA.
- Department of Pediatrics and Human Development, Michigan State College of Human Medicine and Helen DeVos Children's Hospital of Corewell Health, Grand Rapids, MI, USA.
- Department of Pediatrics, Washington University, St. Louis, MO, USA.
- Department of Pediatrics, Stanford School of Medicine, Stanford, CA, USA.
- Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.
- Department of Pediatrics, NYU Grossman School of Medicine, New York, NY, USA.
- Department of Pediatrics, Columbia University, New York, NY, USA.
- Department of Pediatrics, University of Washington School of Medicine, and Division of Infectious Diseases, Seattle Children's Hospital, Seattle, WA, USA.
- Antimicrobial Stewardship Program and Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA.
Abstract
BACKGROUND
Since November 2019, the SARS-CoV-2 pandemic has created challenges for preventing and managing COVID-19 in children and adolescents. Most research to develop new therapeutic interventions or to repurpose existing ones has been undertaken in adults, and although most cases of infection in pediatric populations are mild, there have been many cases of critical and fatal infection. Understanding the risk factors for severe illness and the evidence for safety, efficacy, and effectiveness of therapies for COVID-19 in children is necessary to optimize therapy.
METHODS
A panel of experts in pediatric infectious diseases, pediatric infectious diseases pharmacology, and pediatric intensive care medicine from 21 geographically diverse North American institutions was re-convened. Through a series of teleconferences and web-based surveys and a systematic review with meta-analysis of data for risk factors, a guidance statement comprising a series of recommendations for risk stratification, treatment, and prevention of COVID-19 was developed and refined based on expert consensus.
RESULTS
There are identifiable clinical characteristics that enable risk stratification for patients at risk for severe COVID-19. These risk factors can be used to guide the treatment of hospitalized and non-hospitalized children and adolescents with COVID-19 and to guide preventative therapy where options remain available.
MeSH
Adolescent, Covid-19, Risk Factors, Therapeutics, Communicable Diseases, Infections, Child